RE:CD8+ TiLs and T-cell exhaustionONCY's Bracelet-1 Phase 2 clinical study demonstrated 2 major findings: (1) PD-(L)1 checkpoint inhibitors with an activated Fc region result in T-cell exhaustion and (2) ONCY's pelareorep is effective as a single agent monotherapy + paclitaxel vs paclitaxel alone. AND (3) pelareorep promotes the upregulation of T-cell immune lymphocytes (TiLs) thus overcoming T-cell exhaustion, which ONC's GOBLET-1 Phase 2 cohort studies are showing when pelareorep is combined with the PD-L1 checkpoint inhibitor atezolizumab.